Literature DB >> 31200873

Spectrum of Lung Adenocarcinoma.

Barry D Hutchinson1, Girish S Shroff2, Mylene T Truong2, Jane P Ko3.   

Abstract

Lung cancer remains the most common cause of cancer death in the United States of America and worldwide despite continued advances in lung cancer screening as well as surgical, medical, and radiation oncological treatments. Adenocarcinoma is the most common histological subtype of primary lung cancer and has recently been reorganized into a spectrum ranging from preinvasive lesions to invasive adenocarcinoma. An understanding of the pathology, diagnosis, and management of the spectrum of lung adenocarcinoma is more important than ever, considering the central role of the radiologist. The aim of this review is to describe the subtypes of the lung adenocarcinoma spectrum in terms of histological and imaging features, their pattern of growth on imaging, management, staging, and evolving knowledge of tumor genetics.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2018        PMID: 31200873     DOI: 10.1053/j.sult.2018.11.009

Source DB:  PubMed          Journal:  Semin Ultrasound CT MR        ISSN: 0887-2171            Impact factor:   1.875


  41 in total

1.  MiR-485-5p Suppress the Malignant Characteristics of the Lung Adenocarcinoma via Targeting NADPH Quinone Oxidoreductase-1 to Inhibit the PI3K/Akt.

Authors:  Yupeng Chen; Lin Wu; Min Bao
Journal:  Mol Biotechnol       Date:  2022-10-11       Impact factor: 2.860

2.  Targeting mitochondrial one-carbon enzyme MTHFD2 together with pemetrexed confers therapeutic advantages in lung adenocarcinoma.

Authors:  Juanfen Mo; Zhenzhen Gao; Li Zheng; Miaolong Yan; Min Xue; Jianqiu Xu; Yi Bao; Jiayuan Wu
Journal:  Cell Death Discov       Date:  2022-07-05

3.  Construction of a Novel Prognostic Model in Lung Adenocarcinoma Based on 7-Methylguanosine-Related Gene Signatures.

Authors:  Fei Lu; Jingyan Gao; Yu Hou; Ke Cao; Yaoxiong Xia; Zhengting Chen; Hui Yu; Li Chang; Wenhui Li
Journal:  Front Oncol       Date:  2022-06-16       Impact factor: 5.738

4.  Treatment of a Double Cancer Patient With Primary Inferior Vena Cava Sarcoma and Lung Adenocarcinoma: A Case Report and Literature Review.

Authors:  Xiaohu Guo; Zhengang Wei; Mancai Wang; Youcheng Zhang
Journal:  Front Surg       Date:  2022-04-06

5.  CDK4/6-USP51 axis regulates lung adenocarcinoma metastasis through ZEB1.

Authors:  Jianjun Li; Xuechun Xiao; Hang Wang; Wenhao Wang; Yang Ou; Zhaoyang Wang; Huimin Jiang; Yuxin Liu; Zhen Zhang; Shuang Yang
Journal:  Cancer Gene Ther       Date:  2022-01-20       Impact factor: 5.854

6.  Enhanced glucose metabolism mediated by CD147 is associated with 18 F-FDG PET/CT imaging in lung adenocarcinoma.

Authors:  Yufan Zhang; Jianjing Liu; Yunchuan Sun; Xiaozhou Yu; Jian Wang; Dong Dai; Yanjia Zhu; Xiuyu Song; Lei Zhu; Xiaofeng Li; Wengui Xu
Journal:  Thorac Cancer       Date:  2020-03-11       Impact factor: 3.500

7.  Identification of a six-gene metabolic signature predicting overall survival for patients with lung adenocarcinoma.

Authors:  Yubo Cao; Xiaomei Lu; Yue Li; Jia Fu; Hongyuan Li; Xiulin Li; Ziyou Chang; Sa Liu
Journal:  PeerJ       Date:  2020-12-02       Impact factor: 2.984

8.  Characteristics of the PI3K/AKT and MAPK/ERK pathways involved in the maintenance of self-renewal in lung cancer stem-like cells.

Authors:  Jingyuan Li; Jianyu Wang; Dan Xie; Qin Pei; Xue Wan; H Rosie Xing; Ting Ye
Journal:  Int J Biol Sci       Date:  2021-03-15       Impact factor: 6.580

9.  Mouse lung automated segmentation tool for quantifying lung tumors after micro-computed tomography.

Authors:  Mary Katherine Montgomery; John David; Haikuo Zhang; Sripad Ram; Shibing Deng; Vidya Premkumar; Lisa Manzuk; Ziyue Karen Jiang; Anand Giddabasappa
Journal:  PLoS One       Date:  2021-06-17       Impact factor: 3.240

10.  A Paraneoplastic Leukemoid Reaction in Primary Lung Sarcoma.

Authors:  Ali F Al Sbihi; Nouraldeen Manasrah; Farah M Al Haj; Sarah Al Qasem; Joel Appel
Journal:  Cureus       Date:  2021-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.